Nature Communications (Aug 2018)
March1-dependent modulation of donor MHC II on CD103+ dendritic cells mitigates alloimmunity
- Thiago J. Borges,
- Naoka Murakami,
- Felipe D. Machado,
- Ayesha Murshid,
- Benjamin J. Lang,
- Rafael L. Lopes,
- Laura M. Bellan,
- Mayuko Uehara,
- Krist H. Antunes,
- Maria José Pérez-Saéz,
- Gabriel Birrane,
- Priscila Vianna,
- João Ismael B. Gonçalves,
- Rafael F. Zanin,
- Jamil Azzi,
- Reza Abdi,
- Satoshi Ishido,
- Jeoung-Sook Shin,
- Ana Paula D. Souza,
- Stuart K. Calderwood,
- Leonardo V. Riella,
- Cristina Bonorino
Affiliations
- Thiago J. Borges
- School of Biosciences and Biomedical Research Institute, Pontifícia Universidade Católica do Rio Grande do Sul, PUCRS. Av. Ipiranga
- Naoka Murakami
- Schuster Family Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School
- Felipe D. Machado
- School of Biosciences and Biomedical Research Institute, Pontifícia Universidade Católica do Rio Grande do Sul, PUCRS. Av. Ipiranga
- Ayesha Murshid
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School
- Benjamin J. Lang
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School
- Rafael L. Lopes
- School of Biosciences and Biomedical Research Institute, Pontifícia Universidade Católica do Rio Grande do Sul, PUCRS. Av. Ipiranga
- Laura M. Bellan
- School of Biosciences and Biomedical Research Institute, Pontifícia Universidade Católica do Rio Grande do Sul, PUCRS. Av. Ipiranga
- Mayuko Uehara
- Schuster Family Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School
- Krist H. Antunes
- School of Pharmacy and Centro Infant, Biomedical Research Institute, PUCRS. Av. Ipiranga
- Maria José Pérez-Saéz
- Schuster Family Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School
- Gabriel Birrane
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- Priscila Vianna
- Genetics Department, Universidade Federal do Rio Grande do Sul
- João Ismael B. Gonçalves
- School of Biosciences and Biomedical Research Institute, Pontifícia Universidade Católica do Rio Grande do Sul, PUCRS. Av. Ipiranga
- Rafael F. Zanin
- School of Biosciences and Biomedical Research Institute, Pontifícia Universidade Católica do Rio Grande do Sul, PUCRS. Av. Ipiranga
- Jamil Azzi
- Schuster Family Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School
- Reza Abdi
- Schuster Family Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School
- Satoshi Ishido
- Department of Microbiology, Hyogo College of Medicine
- Jeoung-Sook Shin
- Department of Microbiology and Immunology, Sandler Asthma Basic Research Center, University of California San Francisco
- Ana Paula D. Souza
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- Stuart K. Calderwood
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School
- Leonardo V. Riella
- Schuster Family Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School
- Cristina Bonorino
- School of Biosciences and Biomedical Research Institute, Pontifícia Universidade Católica do Rio Grande do Sul, PUCRS. Av. Ipiranga
- DOI
- https://doi.org/10.1038/s41467-018-05572-z
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 15
Abstract
Donor-derived dendritic cells (do-DC) in the graft can contribute to the induction of alloimmunity and tissue rejection, but how do-DC can be targeted for improving graft survival is unclear. Here the authors show that reducing MHC-II expression on do-DCs by DnaK pre-treatment can decrease the priming of alloimmunity and prolong graft survival in mouse models.
